Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis

K. W. Chan; C. A. Mullen; M. Korbling

doi:10.1038/sj.bmt.1701318

Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis

K. W. Chan, C. A. Mullen, M. Korbling

Stem Cell Transplantation

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation. Successful allogeneic BMT is the only therapy that has produced long-term disease-free survival. However, for patients with active HLH the outcome of BMT remains poor when compared with those transplanted in remission. We describe a patient with active, recurrent HLH treated with highdose chemotherapy and related allogeneic peripheral blood stem cell (PBSC) transplantation. Hematologic recovery was rapid and the post-transplant course was uncomplicated. The patient is alive and well 2 1/4 years after transplant. Allogeneic PBSC transplantation may deserve further evaluation as an alternative source of stem cells for transplantation in patients with active HLH.

Original language	English (US)
Pages (from-to)	301-302
Number of pages	2
Journal	Bone marrow transplantation
Volume	22
Issue number	3
DOIs	https://doi.org/10.1038/sj.bmt.1701318
State	Published - 1998

Keywords

Allogeneic
Hemophagocytic lymphohistiocytosis
Peripheral blood stem cell
Transplantation

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1701318

Cite this

@article{a07ececa3753459186ceb2e4bb837bb5,

title = "Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis",

abstract = "Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation. Successful allogeneic BMT is the only therapy that has produced long-term disease-free survival. However, for patients with active HLH the outcome of BMT remains poor when compared with those transplanted in remission. We describe a patient with active, recurrent HLH treated with highdose chemotherapy and related allogeneic peripheral blood stem cell (PBSC) transplantation. Hematologic recovery was rapid and the post-transplant course was uncomplicated. The patient is alive and well 2 1/4 years after transplant. Allogeneic PBSC transplantation may deserve further evaluation as an alternative source of stem cells for transplantation in patients with active HLH.",

keywords = "Allogeneic, Hemophagocytic lymphohistiocytosis, Peripheral blood stem cell, Transplantation",

author = "Chan, {K. W.} and Mullen, {C. A.} and M. Korbling",

year = "1998",

doi = "10.1038/sj.bmt.1701318",

language = "English (US)",

volume = "22",

pages = "301--302",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis

AU - Chan, K. W.

AU - Mullen, C. A.

AU - Korbling, M.

PY - 1998

Y1 - 1998

N2 - Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation. Successful allogeneic BMT is the only therapy that has produced long-term disease-free survival. However, for patients with active HLH the outcome of BMT remains poor when compared with those transplanted in remission. We describe a patient with active, recurrent HLH treated with highdose chemotherapy and related allogeneic peripheral blood stem cell (PBSC) transplantation. Hematologic recovery was rapid and the post-transplant course was uncomplicated. The patient is alive and well 2 1/4 years after transplant. Allogeneic PBSC transplantation may deserve further evaluation as an alternative source of stem cells for transplantation in patients with active HLH.

AB - Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation. Successful allogeneic BMT is the only therapy that has produced long-term disease-free survival. However, for patients with active HLH the outcome of BMT remains poor when compared with those transplanted in remission. We describe a patient with active, recurrent HLH treated with highdose chemotherapy and related allogeneic peripheral blood stem cell (PBSC) transplantation. Hematologic recovery was rapid and the post-transplant course was uncomplicated. The patient is alive and well 2 1/4 years after transplant. Allogeneic PBSC transplantation may deserve further evaluation as an alternative source of stem cells for transplantation in patients with active HLH.

KW - Allogeneic

KW - Hemophagocytic lymphohistiocytosis

KW - Peripheral blood stem cell

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0031857659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031857659&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701318

DO - 10.1038/sj.bmt.1701318

M3 - Article

C2 - 9720748

AN - SCOPUS:0031857659

SN - 0268-3369

VL - 22

SP - 301

EP - 302

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 3

ER -

Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this